42 completed, 9 terminated, 6 recruiting, 1 active not recruiting. 60 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 60 | Completed 42, Terminated 9, Recruiting 6, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 8 | Completed 6, Recruiting 1, Terminated 1 |
Follow Cyclosporin: new trials by email Literature Review of Cyclosporin trials Research Report on Cyclosporin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Aplastic Anemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 1 | 2025-09-25 | 2026-05-22 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-10-26 |
| Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia Luspatercept, Cyclosporine - Aplastic Anemia | Phase 2 | Completed | Bing Han | 58 | 2022-12-19 | 2025-09-16 |
| Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Cyclosporin, ILT101, Placebo - Type 1 Diabetes | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 24 | 2022-09-21 | 2026-09-09 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide - Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2020-08-19 | 2025-06-29 |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) Total-Body Irradiation, Thiotepa, Fludarabine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2019-11-19 | 2026-10-20 |
| 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Cyclosporine, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 75 | 2017-10-24 | 2026-06-22 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Cladribine, Cyclosporine, Cytarabine - Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia-2 | Phase 2 | Completed | University of Washington | 30 | 2016-09-22 | 2021-11-08 |
| CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Cyclosporine, Mycophenolate Mofetil - Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma | Phase 2 | Completed | Robert Lowsky | 18 | 2015-06-01 | 2021-06-24 |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma rituximab, ibritumomab tiuxetan, anti-thymocyte globulin - Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma | Phase 2 | Unknown | Joseph Tuscano | 20 | 2013-03-12 | 2022-11-30 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate - Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells | Phase 2 | Completed | Fred Hutchinson Cancer Center | 47 | 2012-09-25 | 2020-01-02 |
| Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome Anti-Thymocyte Globulin, Cyclosporine, Filgrastim - Aplastic Anemia, de Novo Myelodysplastic Syndrome | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 140 | 2012-06-25 | 2026-06-22 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia cyclosporine, pravastatin sodium, mitoxantrone hydrochloride - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 6 | 2011-04-01 | 2017-07-02 |
| Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders CIK cells, Cyclosporine, Mycophenolate Mofetil - Neural Tube Defects, Anemia | Phase 2 | Completed | Everett Meyer | 44 | 2011-03-01 | 2019-05-07 |
Showing 20 of 60. Sign in to see all of them.
Leukemia, Myeloid, Acute (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (21) · Leukemia, Lymphocytic, Chronic, B-Cell (20) · Lymphoma, Non-Hodgkin (20) · Hodgkin Disease (16) · Multiple Myeloma (16) · Lymphoma, Large B-Cell, Diffuse (15) · Lymphoma, Mantle-Cell (15) · Leukemia, Myeloid, Chronic-Phase (13) · Myelodysplastic Syndromes (13) · Myeloproliferative Disorders (13) · Waldenstrom Macroglobulinemia (13) · Burkitt Lymphoma (12) · Lymphoma, B-Cell, Marginal Zone (12) · Lymphoma, Follicular (12)
Fred Hutchinson Cancer Center (38) · Stanford University (5) · Case Comprehensive Cancer Center (2) · M.D. Anderson Cancer Center (2) · Assistance Publique - Hôpitaux de Paris (1) · Bing Han (1) · Everett Meyer (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Joseph Tuscano (1) · London School of Hygiene and Tropical Medicine (1) · Masonic Cancer Center, University of Minnesota (1) · National Cancer Institute (NCI) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Nohla Therapeutics, Inc. (1) · Robert Lowsky (1)
United States (57) · Italy (9) · Denmark (2) · Germany (2) · Brazil (1) · China (1) · Ethiopia (1) · France (1)
Brenda Sandmaier (9) · David Maloney (4) · Marco Mielcarek (4) · Wen-Kai Weng (4) · Ajay Gopal (2) · George Georges (2) · Johnnie Orozco (2) · Masumi Ueda Oshima (2) · Robert Lowsky (2) · Ann Dahlberg (1) · Ann E. Dahlberg (1) · Brenda Cooper, MD (1) · Brenda M. Sandmaier (1) · Colleen Delaney (1)
PMID 32499241, PMID 16192477, PMID 19423725, PMID 19900571, PMID 20528878, PMID 21508120, PMID 21508413, PMID 21606164, PMID 24307695, PMID 24607552, PMID 26146806, PMID 26764356, PMID 29296873, PMID 30335787, PMID 30454872, PMID 30630975, PMID 30951840, PMID 31637757, PMID 32603426, PMID 32706891, PMID 32941647, PMID 35445027, PMID 41043099, PMID 42057135
P30CA015704 (28), P01CA018029 (9), P01CA078902 (7), P01CA044991 (2), P01CA049605 (1), P01HL036444 (1), P30CA046592 (1), RC2HL101844 (1)